Get the latest news, insights, and market updates on DWTX (Dogwood Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
DWTX: Positive Interim Results for Halneuron® Phase 2b Trial in CINP; Raising Valuation to $15
By David Bautz, PhD NASDAQ:DWTX READ THE FULL DWTX RESEARCH REPORT Business Update Positive Interim Results for Phase 2b Trial of Halneuron® in CINP On December 22, 2025, Dogwood Therapeutics, Inc. (DWTX) announced positive interim results for the Phase 2b HALT-CINP (Halneuron ® Treatment of Chemotherapy-Induced Neuropathic Pain) trial. Unblinded data from the trial was reviewed by the Dec 30, 2025 - $DWTX
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
- Halneuron® treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 - - The overall study dropout rate of ~4.4% is far below rates typically observed with other FDA approved chronic pain medicines - ATLANTA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announces positive re Dec 22, 2025 - $DWTX
DWTX: Interim Readout for Halneuron® Phase 2b Trial in CINP in 4Q25…
By David Bautz, PhD NASDAQ:DWTX READ THE FULL DWTX RESEARCH REPORT Business Update 100 Patients Enrolled in Phase 2b Trial of Halneuron®; Interim Analysis in 4Q25 Dogwood Therapeutics, Inc. (NASDAQ:DWTX) is currently conducting the Phase 2b HALT-CINP (Halneuron ® Treatment of Chemotherapy-Induced Neuropathic Pain) trial. This is a four-week study that will examine the safety and efficacy of Nov 10, 2025 - $DWTX
Dogwood Therapeutics Reports Third Quarter 2025 Financial Results
- Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron® Phase 2b trial, prespecified interim analysis remains on track for Q4 2025 release - - Secured exclusive worldwide, royalty free license to develop and commercialize SP16 as a synergistic and complementary pipeline treatment for cancer-related pain in an all-stock transaction - ATLANTA, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-sta Nov 6, 2025 - $DWTX
Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025
ATLANTA, GA / ACCESS Newswire / October 14, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathic disorders, today announces that Greg Duncan, ... Oct 14, 2025 - $DWTX
DWTX: Licenses SP16 for Treatment of Cancer Related Pain…
By David Bautz, PhD NASDAQ:DWTX READ THE FULL DWTX RESEARCH REPORT Business Update All-Stock Licensing Deal for Treatment of Cancer Related Pain On September 29, 2025, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) announced a royalty-free, global license deal with Serpin Pharma for SP16 for the management of cancer related pain (CRP), including a broad range of chemotherapy induced neuropathy Oct 10, 2025 - $DWTX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple